Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference

Posted on by

STOCKHOLM, July 20, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results of a detailed analysis of the Phase 3 Clarity AD study, presented at the Alzheimer’s Association International Conference (AAIC) 2023, demonstrated that…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.